董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Ferrari | 男 | Director and Executive Chairman | 72 | 未披露 | 13.53 | 2026-07-23 |
| Steven M. Foster | 男 | Chief Executive Officer and Director and President | 58 | 72.13万美元 | 32.42 | 2026-07-23 |
| Richard Ginn | 男 | Chief Operations Officer and Chief Technology Officer and Director | 60 | 57.86万美元 | 21.22 | 2026-07-23 |
| Ivan Howard | 男 | Director | 58 | 8.90万美元 | 1.93 | 2026-07-23 |
| Robert K. Weigle | 男 | Director | 65 | 9.65万美元 | 1.83 | 2026-07-23 |
| Kristine M. Jacques | 女 | Director | 58 | 7.78万美元 | 2.09 | 2026-07-23 |
| Stephen H. Hochschuler | 男 | Director | 82 | 6.65万美元 | 1.87 | 2026-07-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven M. Foster | 男 | Chief Executive Officer and Director and President | 58 | 72.13万美元 | 32.42 | 2026-07-23 |
| Richard Ginn | 男 | Chief Operations Officer and Chief Technology Officer and Director | 60 | 57.86万美元 | 21.22 | 2026-07-23 |
| Nathaniel Grawey | 男 | Chief Commercial Officer | 43 | 未披露 | 58.40 | 2026-07-23 |
| Wyatt Geist | 男 | Chief Innovation Officer | 57 | 未披露 | 66.42 | 2026-07-23 |
| Kevin Williamson | 男 | Chief Financial Officer and Secretary | 41 | 44.95万美元 | 10.26 | 2026-07-23 |
董事简历
中英对照 | 中文 | 英文- Richard Ferrari
-
Richard Ferrari是该公司的创始人、董事兼执行主席。自2000年以来，法拉利先生一直是并且目前是Denovo Ventures的联合创始人和董事会成员，Denovo Ventures是一家投资6.5亿美元的风险投资公司，专门从事医疗器械和生物技术。从2019年1月到2021年4月，法拉利先生被聘为PQ Bypass的首席执行官兼董事会主席，最终PQ Bypass被恩多勒吉克斯成功收购。法拉利先生于2020年至今担任ABS Interventional的董事会成员（副主席）；于2020年至今担任Heart Beam Inc.的董事会成员（执行主席）；于2015年至今担任Pulmonx的董事会成员（薪酬委员会主席）。法拉利先生已为他所参与的公司筹集了超过10亿美元的资金，并且是各个董事会并购团队中实现超过20亿美元收购的关键成员。法拉利先生继续在战略和建立致力于提供卓越的组织方面为许多首席执行官和初创公司提供指导和建议。法拉利先生是Excellence by Choice系列讲座和演讲的缔造者，旨在帮助处于早期阶段的公司在最高执行水平上表现。法拉利先生获得亚什兰大学教育学学士学位和南佛罗里达大学MBA学位。
Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida. - Richard Ferrari是该公司的创始人、董事兼执行主席。自2000年以来，法拉利先生一直是并且目前是Denovo Ventures的联合创始人和董事会成员，Denovo Ventures是一家投资6.5亿美元的风险投资公司，专门从事医疗器械和生物技术。从2019年1月到2021年4月，法拉利先生被聘为PQ Bypass的首席执行官兼董事会主席，最终PQ Bypass被恩多勒吉克斯成功收购。法拉利先生于2020年至今担任ABS Interventional的董事会成员（副主席）；于2020年至今担任Heart Beam Inc.的董事会成员（执行主席）；于2015年至今担任Pulmonx的董事会成员（薪酬委员会主席）。法拉利先生已为他所参与的公司筹集了超过10亿美元的资金，并且是各个董事会并购团队中实现超过20亿美元收购的关键成员。法拉利先生继续在战略和建立致力于提供卓越的组织方面为许多首席执行官和初创公司提供指导和建议。法拉利先生是Excellence by Choice系列讲座和演讲的缔造者，旨在帮助处于早期阶段的公司在最高执行水平上表现。法拉利先生获得亚什兰大学教育学学士学位和南佛罗里达大学MBA学位。
- Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida.
- Steven M. Foster
-
Steven M. Foster自2021年6月起担任公司首席执行官、总裁和董事。Foster先生拥有超过30年的营销、销售、运营和一般管理经验。从2015年至今，福斯特先生一直担任田纳西州布伦特伍德CTB Advisors，LLC的负责人。CTB Advisors成立时是一家单一成员有限责任公司，目的是为医疗器械组织和医生提供商业化重点项目的咨询协助。项目包括：NuVasive（NUVA）基于CRM的临床医生参与计划设计、培训和实施。包括IP评估和监管路径定义的早期脊柱技术的估值评估/商业计划开发。并购（SafeOp Surgical）整合项目，Alphatec Spine（ATEC）。现状：ATEC独家。2022年3月至今，福斯特先生还一直担任Happe Spine的董事和薪酬委员会成员。从2012年到2014年，Foster先生担任Safe Orthopedics SAS全球商业化总裁，法国巴黎（总部设在密歇根州）：在那里，Foster先生致力于腰椎融合新型单次使用/无菌/可追溯手术套件的早期商业化。他的工作重点包括临床前设计、临床医生顾问团队发展、早期营销、网页设计、会议存在和P & L准备和管理。技术在商业化的前12个月达到了200例全球手术。从1992年到2012年，Foster先生曾任职于Danek Group Inc.、Sofamor Danek、美敦力 Spine组织，在那里他担任过各种营销、销售行政和综合管理职务，包括从2007年至2010年担任美敦力 Spine西欧业务的副总裁/总经理。Foster先生于1990年获得中央密歇根大学市场营销和管理专业的工商管理理学学士学位。
Steven M. Foster is Chief Executive Officer, President, and a director of the Company since June 2021. Mr. Foster has over 30 years of marketing, sales, operations and general management experience. From 2015 to present, Mr. Foster has been a principal with CTB Advisors, LLC in Brentwood, Tennessee. CTB Advisors was founded as a single member limited liability company for the purpose of providing medical device organizations and physicians with consultative assistance on commercialization focused projects. Projects included: CRM based clinician engagement program design, training and implementation for NuVasive (NUVA). Valuation assessment / business plan development of early stage spine technology including IP assessment and regulatory pathway definition. M&A (SafeOp Surgical) integration project, Alphatec Spine (ATEC). Current Status: Exclusive to ATEC. From March 2022 to present, Mr. Foster has also been serving as a director and a member of a compensation committee of Happe Spine. From 2012 to 2014 Mr. Foster was Global Commercialization President of Safe Orthopedics SAS, Paris, FR (based in Michigan): There Mr. Foster worked on early stage commercialization of a novel single use / sterile / traceable surgical kit for lumbar spine fusion. His focus included pre clinical design, clinician advisor team development, early marketing, web design, convention presence and P&L preparation and management. Technology reached 200 global surgeries in first 12 months of commercialization. From 1992 to 2012 Mr. Foster was part of the Danek Group Inc., Sofamor Danek, Medtronic Spine organization where he held a variety of marketing, sales administration and general management roles, including as VP / GM of Medtronic Spine's Western Europe operations from 2007 2010. Mr. Foster received a Bachelor of Science, Business Administration with a concentration in Marketing and Management from Central Michigan University in 1990. - Steven M. Foster自2021年6月起担任公司首席执行官、总裁和董事。Foster先生拥有超过30年的营销、销售、运营和一般管理经验。从2015年至今，福斯特先生一直担任田纳西州布伦特伍德CTB Advisors，LLC的负责人。CTB Advisors成立时是一家单一成员有限责任公司，目的是为医疗器械组织和医生提供商业化重点项目的咨询协助。项目包括：NuVasive（NUVA）基于CRM的临床医生参与计划设计、培训和实施。包括IP评估和监管路径定义的早期脊柱技术的估值评估/商业计划开发。并购（SafeOp Surgical）整合项目，Alphatec Spine（ATEC）。现状：ATEC独家。2022年3月至今，福斯特先生还一直担任Happe Spine的董事和薪酬委员会成员。从2012年到2014年，Foster先生担任Safe Orthopedics SAS全球商业化总裁，法国巴黎（总部设在密歇根州）：在那里，Foster先生致力于腰椎融合新型单次使用/无菌/可追溯手术套件的早期商业化。他的工作重点包括临床前设计、临床医生顾问团队发展、早期营销、网页设计、会议存在和P & L准备和管理。技术在商业化的前12个月达到了200例全球手术。从1992年到2012年，Foster先生曾任职于Danek Group Inc.、Sofamor Danek、美敦力 Spine组织，在那里他担任过各种营销、销售行政和综合管理职务，包括从2007年至2010年担任美敦力 Spine西欧业务的副总裁/总经理。Foster先生于1990年获得中央密歇根大学市场营销和管理专业的工商管理理学学士学位。
- Steven M. Foster is Chief Executive Officer, President, and a director of the Company since June 2021. Mr. Foster has over 30 years of marketing, sales, operations and general management experience. From 2015 to present, Mr. Foster has been a principal with CTB Advisors, LLC in Brentwood, Tennessee. CTB Advisors was founded as a single member limited liability company for the purpose of providing medical device organizations and physicians with consultative assistance on commercialization focused projects. Projects included: CRM based clinician engagement program design, training and implementation for NuVasive (NUVA). Valuation assessment / business plan development of early stage spine technology including IP assessment and regulatory pathway definition. M&A (SafeOp Surgical) integration project, Alphatec Spine (ATEC). Current Status: Exclusive to ATEC. From March 2022 to present, Mr. Foster has also been serving as a director and a member of a compensation committee of Happe Spine. From 2012 to 2014 Mr. Foster was Global Commercialization President of Safe Orthopedics SAS, Paris, FR (based in Michigan): There Mr. Foster worked on early stage commercialization of a novel single use / sterile / traceable surgical kit for lumbar spine fusion. His focus included pre clinical design, clinician advisor team development, early marketing, web design, convention presence and P&L preparation and management. Technology reached 200 global surgeries in first 12 months of commercialization. From 1992 to 2012 Mr. Foster was part of the Danek Group Inc., Sofamor Danek, Medtronic Spine organization where he held a variety of marketing, sales administration and general management roles, including as VP / GM of Medtronic Spine's Western Europe operations from 2007 2010. Mr. Foster received a Bachelor of Science, Business Administration with a concentration in Marketing and Management from Central Michigan University in 1990.
- Richard Ginn
-
Richard Ginn是公司创始人、首席技术官、首席运营官、董事。Ginn先生的工作重点主要是知识产权和产品开发，他曾周游世界各地培训医生，并参与了多项FIH试验，是300多项医疗器械专利的指定发明人。在他的职业生涯中，他帮助筹集了超过1亿美元的风险投资，并为他的投资者提供了平均回报。Ginn先生是栓塞保护装置公司TransAortic Medical的创始人，2013年至今担任该公司总裁、首席执行官和董事。在TransAortic，Ginn先生管理所有企业运营，筹集资金以支持公司需求；管理战略合作伙伴的技术获取；管理所有知识产权；并为CE标志设备设立欧洲分销。Ginn先生是大孔股骨闭合装置公司Promed的创始人，并在2012年至2019年期间担任首席执行官、总裁和董事。在Promed，他管理所有企业运营；筹集资金支持公司需求；并管理所有知识产权。
Richard Ginn is a founder, the Chief Technology Officer, Chief Operations Officer and a director of the Company. Mr. Ginn's focus is primarily on intellectual property and product development, he has travelled throughout the world to train physicians and participated in multiple FIH trials and is a named inventor on more than 300 patents for medical devices. Over the course of his career, he has helped raise more than $100 million in venture capital and has provided an averx return to his investors. Mr. Ginn is the founder of TransAortic Medical, an embolic protection device company, and is its President, CEO and a director from 2013 to present. At TransAortic, Mr. Ginn Managed all corporate operations, raised capital to support company needs; managed acquisition of technology by strategic partner; managed all Intellectual Property; and set up European distribution for CE Marked device. Mr. Ginn is the founder of Promed, a large hole femoral closure device company and was the CEO, President and a director from 2012 to 2019. At Promed he managed all corporate operations; raised capital to support company needs; and managed all intellectual property. - Richard Ginn是公司创始人、首席技术官、首席运营官、董事。Ginn先生的工作重点主要是知识产权和产品开发，他曾周游世界各地培训医生，并参与了多项FIH试验，是300多项医疗器械专利的指定发明人。在他的职业生涯中，他帮助筹集了超过1亿美元的风险投资，并为他的投资者提供了平均回报。Ginn先生是栓塞保护装置公司TransAortic Medical的创始人，2013年至今担任该公司总裁、首席执行官和董事。在TransAortic，Ginn先生管理所有企业运营，筹集资金以支持公司需求；管理战略合作伙伴的技术获取；管理所有知识产权；并为CE标志设备设立欧洲分销。Ginn先生是大孔股骨闭合装置公司Promed的创始人，并在2012年至2019年期间担任首席执行官、总裁和董事。在Promed，他管理所有企业运营；筹集资金支持公司需求；并管理所有知识产权。
- Richard Ginn is a founder, the Chief Technology Officer, Chief Operations Officer and a director of the Company. Mr. Ginn's focus is primarily on intellectual property and product development, he has travelled throughout the world to train physicians and participated in multiple FIH trials and is a named inventor on more than 300 patents for medical devices. Over the course of his career, he has helped raise more than $100 million in venture capital and has provided an averx return to his investors. Mr. Ginn is the founder of TransAortic Medical, an embolic protection device company, and is its President, CEO and a director from 2013 to present. At TransAortic, Mr. Ginn Managed all corporate operations, raised capital to support company needs; managed acquisition of technology by strategic partner; managed all Intellectual Property; and set up European distribution for CE Marked device. Mr. Ginn is the founder of Promed, a large hole femoral closure device company and was the CEO, President and a director from 2012 to 2019. At Promed he managed all corporate operations; raised capital to support company needs; and managed all intellectual property.
- Ivan Howard
-
Ivan Howard为该公司董事。Howard先生自2019年起任职，目前担任跨国金融服务公司桑坦德银行的副总裁兼另类投资信托风险高级专家。Howard先生拥有美世大学MBA学位和佛罗里达大学生物医学工程硕士学位。
Ivan Howard is a director of the Company. Mr. Howard has been since 2019 and currently is a Vice President and Sr. Specialist in Alternative Investment Fiduciary Risk for Banco Santander, a multinational financial services company. Mr. Howard holds an MBA from Mercer University and a Master's Degree in Biomedical Engineering from the University of Florida. - Ivan Howard为该公司董事。Howard先生自2019年起任职，目前担任跨国金融服务公司桑坦德银行的副总裁兼另类投资信托风险高级专家。Howard先生拥有美世大学MBA学位和佛罗里达大学生物医学工程硕士学位。
- Ivan Howard is a director of the Company. Mr. Howard has been since 2019 and currently is a Vice President and Sr. Specialist in Alternative Investment Fiduciary Risk for Banco Santander, a multinational financial services company. Mr. Howard holds an MBA from Mercer University and a Master's Degree in Biomedical Engineering from the University of Florida.
- Robert K. Weigle
-
Robert K. Weigle为公司董事。他目前是并自2020年10月以来一直是Prime Genomics的首席执行官，Prime Genomics是一家利用Genomics的基于唾液的诊断公司。Weigle先生目前也是风险投资公司DigitalDX的常驻高管。Weigle先生在2009年5月至2020年8月期间担任Benvenue Medical的首席执行官和董事。Benvenue是一家位于硅谷的医疗设备公司，筹集了超过2亿美元的资金。在Benvenue，Weigle先生引领了从临床前到成功临床试验的增长，再到在两个不同市场商业化推出第一代设备，一个用于治疗脊柱压缩性骨折，另一个用于治疗退行性椎间盘疾病，导致第一个全年运行率超过每月100万美元。Weigle先生监督了公司战略的所有早期方面，包括定义、沟通和执行公司的整体商业模式；并代表Benvenue向投资界展示。Weigle先生还是众多医疗保健/医疗设备公司的高级主管，包括TherOx，Inc、Cardiac Pathways、Baxter Healthcare和Cardima Corporation。Weigle先生在强生也有相关经验。Weigle先生拥有加州大学伯克利分校政治学学士学位。
Robert K. Weigle is a director of the Company. He currently is and has been since October 2020, the CEO of Prime Genomics, a saliva based diagnostics company utilizing Genomics. Mr. Weigle is also currently an executive in residence with DigitalDX, a venture capital firm. Mr. Weigle was CEO and a director of Benvenue Medical from May 2009 until August 2020. Benvenue was a Silicon Valley based medical device company, which raised over $200 million in funding. At Benvenue Mr. Weigle led growth from pre clinical to successful clinical trials to commercial launch of first generation devices in two distinct markets, one for the treatment of compression fractures in the spine and the second for the treatment of degenerative disc disease, resulting in a first full year run rate exceeding $1 million per month. Mr. Weigle oversaw all early aspects of corporate strategy, including defining, communicating and executing the company's overall business model; and represented Benvenue to the investment community. Mr. Weigle was also a senior executive at numerous healthcare/medical device companies, including TherOx, Inc, Cardiac Pathways, Baxter Healthcare and Cardima Corporation. Mr. Weigle also has relevant experience at Johnson & Johnson. Mr. Weigle holds a BA in Political Science from University of California, Berkeley. - Robert K. Weigle为公司董事。他目前是并自2020年10月以来一直是Prime Genomics的首席执行官，Prime Genomics是一家利用Genomics的基于唾液的诊断公司。Weigle先生目前也是风险投资公司DigitalDX的常驻高管。Weigle先生在2009年5月至2020年8月期间担任Benvenue Medical的首席执行官和董事。Benvenue是一家位于硅谷的医疗设备公司，筹集了超过2亿美元的资金。在Benvenue，Weigle先生引领了从临床前到成功临床试验的增长，再到在两个不同市场商业化推出第一代设备，一个用于治疗脊柱压缩性骨折，另一个用于治疗退行性椎间盘疾病，导致第一个全年运行率超过每月100万美元。Weigle先生监督了公司战略的所有早期方面，包括定义、沟通和执行公司的整体商业模式；并代表Benvenue向投资界展示。Weigle先生还是众多医疗保健/医疗设备公司的高级主管，包括TherOx，Inc、Cardiac Pathways、Baxter Healthcare和Cardima Corporation。Weigle先生在强生也有相关经验。Weigle先生拥有加州大学伯克利分校政治学学士学位。
- Robert K. Weigle is a director of the Company. He currently is and has been since October 2020, the CEO of Prime Genomics, a saliva based diagnostics company utilizing Genomics. Mr. Weigle is also currently an executive in residence with DigitalDX, a venture capital firm. Mr. Weigle was CEO and a director of Benvenue Medical from May 2009 until August 2020. Benvenue was a Silicon Valley based medical device company, which raised over $200 million in funding. At Benvenue Mr. Weigle led growth from pre clinical to successful clinical trials to commercial launch of first generation devices in two distinct markets, one for the treatment of compression fractures in the spine and the second for the treatment of degenerative disc disease, resulting in a first full year run rate exceeding $1 million per month. Mr. Weigle oversaw all early aspects of corporate strategy, including defining, communicating and executing the company's overall business model; and represented Benvenue to the investment community. Mr. Weigle was also a senior executive at numerous healthcare/medical device companies, including TherOx, Inc, Cardiac Pathways, Baxter Healthcare and Cardima Corporation. Mr. Weigle also has relevant experience at Johnson & Johnson. Mr. Weigle holds a BA in Political Science from University of California, Berkeley.
- Kristine M. Jacques
-
Kristine M. Jacques于2024年3月25日获委任为公司董事。2023年3月至今，Jacques女士一直担任咨询服务公司KJ VB MedTech Consulting，LLC的总经理。从2019年11月到2023年1月，Jacques女士担任Vivex Biologics，Inc.的副总裁兼介入疼痛疗法总经理，该公司是一家医疗设备公司，在那里她实施了一项全面的战略计划，即在介入脊柱市场采用颠覆性技术，服务于重大未满足的临床需求和潜在的380亿美元外加总可寻址市场，用于慢性腰痛的非手术治疗。2007年至2017年，Jacques女士担任Alphatec Spine，Inc（纳斯达克：ATEC）的副总裁，该公司是一家医疗器械公司，在那里她领导了3年投资组合战略的开发和执行，通过识别创新机会、最大限度地提高产品定位和差异化以及提供高质量产品来满足外科医生及其患者的临床和未满足的需求来增加市场份额。从1995年到2007年，Jacques女士曾在通用电气公司担任多个管理职务，在此之前，她曾于1991年至1994年在施乐辉，PLC担任多个管理职务，这两家公司都是上市公司。此前，她于1988年至1991年担任通用电气资本公司客户经理、高级投资分析师。Jacques女士获得密歇根州立大学财务管理文学学士学位。
Kristine M. Jacques was appointed as a director of the Company on March 25, 2024. From March 2023 to present Ms. Jacques has been serving as a General Manager of Kj VB MedTech Consulting, LLC, a consulting services company. From November 2019 until January 2023, Ms. Jacques was Vice President and General Manager, Interventional Pain Therapies at Vivex Biologics, Inc., a medical device company where she implemented a comprehensive strategic plan of a disruptive technology in the interventional spine market serving a significant unmet clinical need and potential $38 billion plus total addressable market, non surgical treatment for chronic low back pain. From 2007 to 2017, Ms. Jacques was a Vice President at Alphatec Spine, Inc (Nasdaq:ATEC), a medical device company where she led the development and execution of a 3 year portfolio strategy to grow market share through identifying opportunities for innovation, maximizing product positioning and differentiation and delivering high quality products to meet the clinical and unmet needs of surgeons and their patients. From 1995 until 2007, Ms. Jacques served in various management positions at General Electric Corporation, prior to which she served from 1991 until 1994 at various management positions at Smith & Nephew, PLC, both of which are publicly traded. Previously, she was an Account Manager, Senior Investment Analyst for General Electric Capital Corporation from 1988 until 1991. Ms. Jacques received a Bachelor of Arts degree in Finance Administration from Michigan State University. - Kristine M. Jacques于2024年3月25日获委任为公司董事。2023年3月至今，Jacques女士一直担任咨询服务公司KJ VB MedTech Consulting，LLC的总经理。从2019年11月到2023年1月，Jacques女士担任Vivex Biologics，Inc.的副总裁兼介入疼痛疗法总经理，该公司是一家医疗设备公司，在那里她实施了一项全面的战略计划，即在介入脊柱市场采用颠覆性技术，服务于重大未满足的临床需求和潜在的380亿美元外加总可寻址市场，用于慢性腰痛的非手术治疗。2007年至2017年，Jacques女士担任Alphatec Spine，Inc（纳斯达克：ATEC）的副总裁，该公司是一家医疗器械公司，在那里她领导了3年投资组合战略的开发和执行，通过识别创新机会、最大限度地提高产品定位和差异化以及提供高质量产品来满足外科医生及其患者的临床和未满足的需求来增加市场份额。从1995年到2007年，Jacques女士曾在通用电气公司担任多个管理职务，在此之前，她曾于1991年至1994年在施乐辉，PLC担任多个管理职务，这两家公司都是上市公司。此前，她于1988年至1991年担任通用电气资本公司客户经理、高级投资分析师。Jacques女士获得密歇根州立大学财务管理文学学士学位。
- Kristine M. Jacques was appointed as a director of the Company on March 25, 2024. From March 2023 to present Ms. Jacques has been serving as a General Manager of Kj VB MedTech Consulting, LLC, a consulting services company. From November 2019 until January 2023, Ms. Jacques was Vice President and General Manager, Interventional Pain Therapies at Vivex Biologics, Inc., a medical device company where she implemented a comprehensive strategic plan of a disruptive technology in the interventional spine market serving a significant unmet clinical need and potential $38 billion plus total addressable market, non surgical treatment for chronic low back pain. From 2007 to 2017, Ms. Jacques was a Vice President at Alphatec Spine, Inc (Nasdaq:ATEC), a medical device company where she led the development and execution of a 3 year portfolio strategy to grow market share through identifying opportunities for innovation, maximizing product positioning and differentiation and delivering high quality products to meet the clinical and unmet needs of surgeons and their patients. From 1995 until 2007, Ms. Jacques served in various management positions at General Electric Corporation, prior to which she served from 1991 until 1994 at various management positions at Smith & Nephew, PLC, both of which are publicly traded. Previously, she was an Account Manager, Senior Investment Analyst for General Electric Capital Corporation from 1988 until 1991. Ms. Jacques received a Bachelor of Arts degree in Finance Administration from Michigan State University.
- Stephen H. Hochschuler
-
Stephen H. Hochschuler， 医学博士。2006年10月起，他担任Tenon Medical, Inc.和Alphatec Spine的董事。2005年10月起，他担任Tenon Medical, Inc.科技咨询董事会的主席。他是Texas Back Institute的主席和创始人之一；1980年起担任主席。1977年起，他成为脊椎病症专业整形外科医师，他在德克萨斯州普莱诺完成外科实践。他是Spine Arthroplasty Society，即现在的International Society for the Advancement of Spine Surgery的创始人和前总裁。他还是北美脊椎协会（North American Spine Society）、德克萨斯州医疗协会（Texas Medical Association）和美国整形外科手术学会（American Academy of Orthopedic Surgeons）的活跃成员。
Stephen H. Hochschuler is a director of the Company. Dr. Hochschuler is a world renowned orthopedic spine surgeon. Dr. Hochschuler is the co founder of the Texas Back Institute and founder of Back Systems, Inc., and founding Chairman of Innovative Spinal Technologies, Dr. Hochschuler has severed on numerous boards of directors and advisory boards for medical and scientific institutions. Dr. Hochschuler is a member of numerous national and international professional organizations including the American Academy of Orthopedic Surgeons; the American Pain Society; North American Spine Society; and the Southwest Chapter of the Society of International Business Fellows. Internationally, he is a member of the International Intradiscal Therapy Society; the International Society for Minimal Intervention in Spinal Surgery; the International Society for the Study of the Lumbar Spine; and is a founding board member of the Spinal Arthroplasty Society. He has also been a founding board member of The American Board of Spine Surgery and The American College of Spine Surgery. He is published in a wide range of professional journals and has delivered numerous presentations worldwide. Dr. Hochschuler holds a BA from Columbia College and his medical degree from Harvard Medical School. - Stephen H. Hochschuler， 医学博士。2006年10月起，他担任Tenon Medical, Inc.和Alphatec Spine的董事。2005年10月起，他担任Tenon Medical, Inc.科技咨询董事会的主席。他是Texas Back Institute的主席和创始人之一；1980年起担任主席。1977年起，他成为脊椎病症专业整形外科医师，他在德克萨斯州普莱诺完成外科实践。他是Spine Arthroplasty Society，即现在的International Society for the Advancement of Spine Surgery的创始人和前总裁。他还是北美脊椎协会（North American Spine Society）、德克萨斯州医疗协会（Texas Medical Association）和美国整形外科手术学会（American Academy of Orthopedic Surgeons）的活跃成员。
- Stephen H. Hochschuler is a director of the Company. Dr. Hochschuler is a world renowned orthopedic spine surgeon. Dr. Hochschuler is the co founder of the Texas Back Institute and founder of Back Systems, Inc., and founding Chairman of Innovative Spinal Technologies, Dr. Hochschuler has severed on numerous boards of directors and advisory boards for medical and scientific institutions. Dr. Hochschuler is a member of numerous national and international professional organizations including the American Academy of Orthopedic Surgeons; the American Pain Society; North American Spine Society; and the Southwest Chapter of the Society of International Business Fellows. Internationally, he is a member of the International Intradiscal Therapy Society; the International Society for Minimal Intervention in Spinal Surgery; the International Society for the Study of the Lumbar Spine; and is a founding board member of the Spinal Arthroplasty Society. He has also been a founding board member of The American Board of Spine Surgery and The American College of Spine Surgery. He is published in a wide range of professional journals and has delivered numerous presentations worldwide. Dr. Hochschuler holds a BA from Columbia College and his medical degree from Harvard Medical School.
高管简历
中英对照 | 中文 | 英文- Steven M. Foster
Steven M. Foster自2021年6月起担任公司首席执行官、总裁和董事。Foster先生拥有超过30年的营销、销售、运营和一般管理经验。从2015年至今，福斯特先生一直担任田纳西州布伦特伍德CTB Advisors，LLC的负责人。CTB Advisors成立时是一家单一成员有限责任公司，目的是为医疗器械组织和医生提供商业化重点项目的咨询协助。项目包括：NuVasive（NUVA）基于CRM的临床医生参与计划设计、培训和实施。包括IP评估和监管路径定义的早期脊柱技术的估值评估/商业计划开发。并购（SafeOp Surgical）整合项目，Alphatec Spine（ATEC）。现状：ATEC独家。2022年3月至今，福斯特先生还一直担任Happe Spine的董事和薪酬委员会成员。从2012年到2014年，Foster先生担任Safe Orthopedics SAS全球商业化总裁，法国巴黎（总部设在密歇根州）：在那里，Foster先生致力于腰椎融合新型单次使用/无菌/可追溯手术套件的早期商业化。他的工作重点包括临床前设计、临床医生顾问团队发展、早期营销、网页设计、会议存在和P & L准备和管理。技术在商业化的前12个月达到了200例全球手术。从1992年到2012年，Foster先生曾任职于Danek Group Inc.、Sofamor Danek、美敦力 Spine组织，在那里他担任过各种营销、销售行政和综合管理职务，包括从2007年至2010年担任美敦力 Spine西欧业务的副总裁/总经理。Foster先生于1990年获得中央密歇根大学市场营销和管理专业的工商管理理学学士学位。
Steven M. Foster is Chief Executive Officer, President, and a director of the Company since June 2021. Mr. Foster has over 30 years of marketing, sales, operations and general management experience. From 2015 to present, Mr. Foster has been a principal with CTB Advisors, LLC in Brentwood, Tennessee. CTB Advisors was founded as a single member limited liability company for the purpose of providing medical device organizations and physicians with consultative assistance on commercialization focused projects. Projects included: CRM based clinician engagement program design, training and implementation for NuVasive (NUVA). Valuation assessment / business plan development of early stage spine technology including IP assessment and regulatory pathway definition. M&A (SafeOp Surgical) integration project, Alphatec Spine (ATEC). Current Status: Exclusive to ATEC. From March 2022 to present, Mr. Foster has also been serving as a director and a member of a compensation committee of Happe Spine. From 2012 to 2014 Mr. Foster was Global Commercialization President of Safe Orthopedics SAS, Paris, FR (based in Michigan): There Mr. Foster worked on early stage commercialization of a novel single use / sterile / traceable surgical kit for lumbar spine fusion. His focus included pre clinical design, clinician advisor team development, early marketing, web design, convention presence and P&L preparation and management. Technology reached 200 global surgeries in first 12 months of commercialization. From 1992 to 2012 Mr. Foster was part of the Danek Group Inc., Sofamor Danek, Medtronic Spine organization where he held a variety of marketing, sales administration and general management roles, including as VP / GM of Medtronic Spine's Western Europe operations from 2007 2010. Mr. Foster received a Bachelor of Science, Business Administration with a concentration in Marketing and Management from Central Michigan University in 1990.- Steven M. Foster自2021年6月起担任公司首席执行官、总裁和董事。Foster先生拥有超过30年的营销、销售、运营和一般管理经验。从2015年至今，福斯特先生一直担任田纳西州布伦特伍德CTB Advisors，LLC的负责人。CTB Advisors成立时是一家单一成员有限责任公司，目的是为医疗器械组织和医生提供商业化重点项目的咨询协助。项目包括：NuVasive（NUVA）基于CRM的临床医生参与计划设计、培训和实施。包括IP评估和监管路径定义的早期脊柱技术的估值评估/商业计划开发。并购（SafeOp Surgical）整合项目，Alphatec Spine（ATEC）。现状：ATEC独家。2022年3月至今，福斯特先生还一直担任Happe Spine的董事和薪酬委员会成员。从2012年到2014年，Foster先生担任Safe Orthopedics SAS全球商业化总裁，法国巴黎（总部设在密歇根州）：在那里，Foster先生致力于腰椎融合新型单次使用/无菌/可追溯手术套件的早期商业化。他的工作重点包括临床前设计、临床医生顾问团队发展、早期营销、网页设计、会议存在和P & L准备和管理。技术在商业化的前12个月达到了200例全球手术。从1992年到2012年，Foster先生曾任职于Danek Group Inc.、Sofamor Danek、美敦力 Spine组织，在那里他担任过各种营销、销售行政和综合管理职务，包括从2007年至2010年担任美敦力 Spine西欧业务的副总裁/总经理。Foster先生于1990年获得中央密歇根大学市场营销和管理专业的工商管理理学学士学位。
- Steven M. Foster is Chief Executive Officer, President, and a director of the Company since June 2021. Mr. Foster has over 30 years of marketing, sales, operations and general management experience. From 2015 to present, Mr. Foster has been a principal with CTB Advisors, LLC in Brentwood, Tennessee. CTB Advisors was founded as a single member limited liability company for the purpose of providing medical device organizations and physicians with consultative assistance on commercialization focused projects. Projects included: CRM based clinician engagement program design, training and implementation for NuVasive (NUVA). Valuation assessment / business plan development of early stage spine technology including IP assessment and regulatory pathway definition. M&A (SafeOp Surgical) integration project, Alphatec Spine (ATEC). Current Status: Exclusive to ATEC. From March 2022 to present, Mr. Foster has also been serving as a director and a member of a compensation committee of Happe Spine. From 2012 to 2014 Mr. Foster was Global Commercialization President of Safe Orthopedics SAS, Paris, FR (based in Michigan): There Mr. Foster worked on early stage commercialization of a novel single use / sterile / traceable surgical kit for lumbar spine fusion. His focus included pre clinical design, clinician advisor team development, early marketing, web design, convention presence and P&L preparation and management. Technology reached 200 global surgeries in first 12 months of commercialization. From 1992 to 2012 Mr. Foster was part of the Danek Group Inc., Sofamor Danek, Medtronic Spine organization where he held a variety of marketing, sales administration and general management roles, including as VP / GM of Medtronic Spine's Western Europe operations from 2007 2010. Mr. Foster received a Bachelor of Science, Business Administration with a concentration in Marketing and Management from Central Michigan University in 1990.
- Richard Ginn
Richard Ginn是公司创始人、首席技术官、首席运营官、董事。Ginn先生的工作重点主要是知识产权和产品开发，他曾周游世界各地培训医生，并参与了多项FIH试验，是300多项医疗器械专利的指定发明人。在他的职业生涯中，他帮助筹集了超过1亿美元的风险投资，并为他的投资者提供了平均回报。Ginn先生是栓塞保护装置公司TransAortic Medical的创始人，2013年至今担任该公司总裁、首席执行官和董事。在TransAortic，Ginn先生管理所有企业运营，筹集资金以支持公司需求；管理战略合作伙伴的技术获取；管理所有知识产权；并为CE标志设备设立欧洲分销。Ginn先生是大孔股骨闭合装置公司Promed的创始人，并在2012年至2019年期间担任首席执行官、总裁和董事。在Promed，他管理所有企业运营；筹集资金支持公司需求；并管理所有知识产权。
Richard Ginn is a founder, the Chief Technology Officer, Chief Operations Officer and a director of the Company. Mr. Ginn's focus is primarily on intellectual property and product development, he has travelled throughout the world to train physicians and participated in multiple FIH trials and is a named inventor on more than 300 patents for medical devices. Over the course of his career, he has helped raise more than $100 million in venture capital and has provided an averx return to his investors. Mr. Ginn is the founder of TransAortic Medical, an embolic protection device company, and is its President, CEO and a director from 2013 to present. At TransAortic, Mr. Ginn Managed all corporate operations, raised capital to support company needs; managed acquisition of technology by strategic partner; managed all Intellectual Property; and set up European distribution for CE Marked device. Mr. Ginn is the founder of Promed, a large hole femoral closure device company and was the CEO, President and a director from 2012 to 2019. At Promed he managed all corporate operations; raised capital to support company needs; and managed all intellectual property.- Richard Ginn是公司创始人、首席技术官、首席运营官、董事。Ginn先生的工作重点主要是知识产权和产品开发，他曾周游世界各地培训医生，并参与了多项FIH试验，是300多项医疗器械专利的指定发明人。在他的职业生涯中，他帮助筹集了超过1亿美元的风险投资，并为他的投资者提供了平均回报。Ginn先生是栓塞保护装置公司TransAortic Medical的创始人，2013年至今担任该公司总裁、首席执行官和董事。在TransAortic，Ginn先生管理所有企业运营，筹集资金以支持公司需求；管理战略合作伙伴的技术获取；管理所有知识产权；并为CE标志设备设立欧洲分销。Ginn先生是大孔股骨闭合装置公司Promed的创始人，并在2012年至2019年期间担任首席执行官、总裁和董事。在Promed，他管理所有企业运营；筹集资金支持公司需求；并管理所有知识产权。
- Richard Ginn is a founder, the Chief Technology Officer, Chief Operations Officer and a director of the Company. Mr. Ginn's focus is primarily on intellectual property and product development, he has travelled throughout the world to train physicians and participated in multiple FIH trials and is a named inventor on more than 300 patents for medical devices. Over the course of his career, he has helped raise more than $100 million in venture capital and has provided an averx return to his investors. Mr. Ginn is the founder of TransAortic Medical, an embolic protection device company, and is its President, CEO and a director from 2013 to present. At TransAortic, Mr. Ginn Managed all corporate operations, raised capital to support company needs; managed acquisition of technology by strategic partner; managed all Intellectual Property; and set up European distribution for CE Marked device. Mr. Ginn is the founder of Promed, a large hole femoral closure device company and was the CEO, President and a director from 2012 to 2019. At Promed he managed all corporate operations; raised capital to support company needs; and managed all intellectual property.
- Nathaniel Grawey
纳撒尼尔·格拉维（Nathaniel Grawey）担任首席商务官，自2025年8月起任职。Grawey先生最近于2023年7月至2025年4月担任SiVantage，Inc.的联合创始人和总裁，SiVantage，Inc.是一家专注于骶髂关节融合技术的医疗设备公司，其资产于2025年8月被公司收购。从2022年到2023年，Grawey先生在Accelus Inc.担任业务发展总监，这是一家专注于可扩展脊柱植入技术的医疗设备公司，负责商业化战略和市场开发计划。Grawey先生于2011年3月至2022年7月在医疗技术公司美敦力 PLC担任高级现场销售代表，负责管理脊柱产品组合并支持手术技术的采用。Grawey先生拥有Embry Riddle航空大学的航空科学学士学位和路易斯安那州立大学什里夫波特分校的工商管理硕士学位。
Nathaniel Grawey is Chief Commercial Officer, where he has served since August of 2025. Mr. Grawey most recently served from July 2023 to April 2025 as the Co Founder and President of SiVantage, Inc., a medical device company focused on sacroiliac joint fusion technologies whose assets were acquired by the Company in August 2025. From 2022 to 2023, Mr. Grawey served as Director of Business Development at Accelus Inc., a medical device company focused on expandable spinal implant technology where he was responsible for commercialization strategy and market development initiatives. Mr. Grawey served as a Senior Field Sales Representative at Medtronic plc, a medical technology company, from March 2011 to July 2022 where he managed spine product portfolios and supported the adoption of surgical technologies. Mr. Grawey holds a B.S. in Aeronautical Science from Embry Riddle Aeronautical University and an M.B.A. from Louisiana State University Shreveport.- 纳撒尼尔·格拉维（Nathaniel Grawey）担任首席商务官，自2025年8月起任职。Grawey先生最近于2023年7月至2025年4月担任SiVantage，Inc.的联合创始人和总裁，SiVantage，Inc.是一家专注于骶髂关节融合技术的医疗设备公司，其资产于2025年8月被公司收购。从2022年到2023年，Grawey先生在Accelus Inc.担任业务发展总监，这是一家专注于可扩展脊柱植入技术的医疗设备公司，负责商业化战略和市场开发计划。Grawey先生于2011年3月至2022年7月在医疗技术公司美敦力 PLC担任高级现场销售代表，负责管理脊柱产品组合并支持手术技术的采用。Grawey先生拥有Embry Riddle航空大学的航空科学学士学位和路易斯安那州立大学什里夫波特分校的工商管理硕士学位。
- Nathaniel Grawey is Chief Commercial Officer, where he has served since August of 2025. Mr. Grawey most recently served from July 2023 to April 2025 as the Co Founder and President of SiVantage, Inc., a medical device company focused on sacroiliac joint fusion technologies whose assets were acquired by the Company in August 2025. From 2022 to 2023, Mr. Grawey served as Director of Business Development at Accelus Inc., a medical device company focused on expandable spinal implant technology where he was responsible for commercialization strategy and market development initiatives. Mr. Grawey served as a Senior Field Sales Representative at Medtronic plc, a medical technology company, from March 2011 to July 2022 where he managed spine product portfolios and supported the adoption of surgical technologies. Mr. Grawey holds a B.S. in Aeronautical Science from Embry Riddle Aeronautical University and an M.B.A. from Louisiana State University Shreveport.
- Wyatt Geist
Wyatt Geist是首席创新官，自2025年8月起任职。目前，Geist先生还担任GeoToll Inc.的董事长（自2012年4月起），这是一家使用增强型GPS通过智能手机实现收费的e业务，以及Mergeit.AI的合伙人（自2025年8月起）。2023年2月至2025年7月，Geist先生担任SiVantage，Inc.的首席执行官和唯一董事会成员，SiVantage，Inc.是一家专注于骶髂关节融合技术的医疗设备公司，其资产于2025年8月被公司收购。Geist先生曾于2016年4月至2022年12月担任Accelus，Inc.的首席技术官和董事会成员，该公司是一家专注于可扩展脊柱植入物技术的医疗设备公司。Geist先生拥有奥本大学微生物学学士学位。
Wyatt Geist is Chief Innovation Officer, where he has served since August of 2025. Currently Mr. Geist also serves as Chairman for GeoToll Inc. (since April 2012), an e business that uses enhanced GPS to make tolling possible via smartphones, and Partner at Mergeit.AI (since August 2025). From February 2023 to July 2025 Mr. Geist served as Chief Executive Officer and sole board member for SiVantage, Inc., a medical device company focused on sacroiliac joint fusion technologies whose assets were acquired by the Company in August 2025. Mr. Geist served as Chief Technology Officer and board member for Accelus, Inc., a medical device company focused on expandable spinal implant technology, from April 2016 to December 2022. Mr. Geist holds a B.S. in Microbiology from Auburn University.- Wyatt Geist是首席创新官，自2025年8月起任职。目前，Geist先生还担任GeoToll Inc.的董事长（自2012年4月起），这是一家使用增强型GPS通过智能手机实现收费的e业务，以及Mergeit.AI的合伙人（自2025年8月起）。2023年2月至2025年7月，Geist先生担任SiVantage，Inc.的首席执行官和唯一董事会成员，SiVantage，Inc.是一家专注于骶髂关节融合技术的医疗设备公司，其资产于2025年8月被公司收购。Geist先生曾于2016年4月至2022年12月担任Accelus，Inc.的首席技术官和董事会成员，该公司是一家专注于可扩展脊柱植入物技术的医疗设备公司。Geist先生拥有奥本大学微生物学学士学位。
- Wyatt Geist is Chief Innovation Officer, where he has served since August of 2025. Currently Mr. Geist also serves as Chairman for GeoToll Inc. (since April 2012), an e business that uses enhanced GPS to make tolling possible via smartphones, and Partner at Mergeit.AI (since August 2025). From February 2023 to July 2025 Mr. Geist served as Chief Executive Officer and sole board member for SiVantage, Inc., a medical device company focused on sacroiliac joint fusion technologies whose assets were acquired by the Company in August 2025. Mr. Geist served as Chief Technology Officer and board member for Accelus, Inc., a medical device company focused on expandable spinal implant technology, from April 2016 to December 2022. Mr. Geist holds a B.S. in Microbiology from Auburn University.
- Kevin Williamson
Kevin Williamson是首席财务官。Williamson先生自2024年9月3日起担任首席财务官。在加入公司之前，Kevin Williamson曾在Accelus Inc.担任首席财务官，这是一家总部位于佛罗里达州的医疗设备公司，专注于可扩展脊柱植入物技术。在担任这一职务期间，自2020年4月至2024年6月，Williamson先生负责财务组织、投资者关系和信息技术职能。在担任此职务之前，Williamson先生于2019年2月至2020年4月担任Accelus Inc.的财务总监，负责财务规划和分析。从2015年到2019年，威廉森先生在NuVasive，Inc.的企业财务部门担任了越来越多的职务，这是一家总部位于加利福尼亚州的医疗设备公司，专注于脊柱微创手术。Williamson先生拥有圣地亚哥州立大学工商管理、金融学士学位和圣地亚哥大学克瑙斯商学院工商管理硕士学位。
Kevin Williamson is Chief Financial Officer. Mr. Williamson has been the Chief Financial Officer since September 3, 2024. Before joining the Company, Kevin Williamson served as the Chief Financial Officer at Accelus Inc., a Florida based medical device company focused on expandable spinal implant technology. In this role, from April 2020 to June 2024, Mr. Williamson was responsible for the Finance organization, Investor Relations and information technology functions. Prior to this role, Mr. Williamson served as the Director of Finance at Accelus Inc. from February 2019 to April 2020, where he was responsible for Financial Planning and Analysis. From 2015 to 2019 Mr. Williamson held various roles of increasing responsibility in the Corporate Finance department at NuVasive, Inc., a California based medical device company focused on minimally invasive spine surgery. Mr. Williamson holds a B.S. in Business Administration, Finance from San Diego State University and an M.B.A. from the University of San Diego Knauss School of Business.- Kevin Williamson是首席财务官。Williamson先生自2024年9月3日起担任首席财务官。在加入公司之前，Kevin Williamson曾在Accelus Inc.担任首席财务官，这是一家总部位于佛罗里达州的医疗设备公司，专注于可扩展脊柱植入物技术。在担任这一职务期间，自2020年4月至2024年6月，Williamson先生负责财务组织、投资者关系和信息技术职能。在担任此职务之前，Williamson先生于2019年2月至2020年4月担任Accelus Inc.的财务总监，负责财务规划和分析。从2015年到2019年，威廉森先生在NuVasive，Inc.的企业财务部门担任了越来越多的职务，这是一家总部位于加利福尼亚州的医疗设备公司，专注于脊柱微创手术。Williamson先生拥有圣地亚哥州立大学工商管理、金融学士学位和圣地亚哥大学克瑙斯商学院工商管理硕士学位。
- Kevin Williamson is Chief Financial Officer. Mr. Williamson has been the Chief Financial Officer since September 3, 2024. Before joining the Company, Kevin Williamson served as the Chief Financial Officer at Accelus Inc., a Florida based medical device company focused on expandable spinal implant technology. In this role, from April 2020 to June 2024, Mr. Williamson was responsible for the Finance organization, Investor Relations and information technology functions. Prior to this role, Mr. Williamson served as the Director of Finance at Accelus Inc. from February 2019 to April 2020, where he was responsible for Financial Planning and Analysis. From 2015 to 2019 Mr. Williamson held various roles of increasing responsibility in the Corporate Finance department at NuVasive, Inc., a California based medical device company focused on minimally invasive spine surgery. Mr. Williamson holds a B.S. in Business Administration, Finance from San Diego State University and an M.B.A. from the University of San Diego Knauss School of Business.